The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization
- PMID: 33670699
- PMCID: PMC7922586
- DOI: 10.3390/diagnostics11020339
The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization
Abstract
Current pathology practice is being shaped by the increasing complexity of modern medicine, in particular of precision oncology, and major technological advances. In the "next-generation technologies era", the pathologist has become the person responsible for the integration and interpretation of morphologic and molecular information and for the delivery of critical answers to diagnostic, prognostic and predictive queries, acquiring a prominent position in the molecular tumor boards.
Keywords: molecular pathology; next generation technologies; oncology; predictive biomarkers.
Conflict of interest statement
The authors have no competing interests to declare related to the presented work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
Similar articles
-
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice.Pathologica. 2020 Sep;112(3):248-259. doi: 10.32074/1591-951X-158. Pathologica. 2020. PMID: 33179625 Free PMC article. Review.
-
Molecular Diagnostics in Pathology: Time for a Next-Generation Pathologist?Arch Pathol Lab Med. 2018 Mar;142(3):313-320. doi: 10.5858/arpa.2017-0269-RA. Arch Pathol Lab Med. 2018. PMID: 29494219 Review.
-
Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT).Cancers (Basel). 2020 Jun 19;12(6):1627. doi: 10.3390/cancers12061627. Cancers (Basel). 2020. PMID: 32575424 Free PMC article.
-
Tissue management in precision medicine: What the pathologist needs to know in the molecular era.Front Mol Biosci. 2022 Oct 26;9:983102. doi: 10.3389/fmolb.2022.983102. eCollection 2022. Front Mol Biosci. 2022. PMID: 36387281 Free PMC article. Review.
-
Molecular Tumor Boards: Realizing Precision Oncology Therapy.Clin Pharmacol Ther. 2018 Feb;103(2):206-209. doi: 10.1002/cpt.920. Epub 2017 Nov 14. Clin Pharmacol Ther. 2018. PMID: 29134641 Free PMC article.
Cited by
-
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies.Cancers (Basel). 2023 Nov 15;15(22):5430. doi: 10.3390/cancers15225430. Cancers (Basel). 2023. PMID: 38001690 Free PMC article. Review.
-
Current challenges and practical aspects of molecular pathology for non-small cell lung cancers.Virchows Arch. 2023 Oct 6. doi: 10.1007/s00428-023-03651-1. Online ahead of print. Virchows Arch. 2023. PMID: 37801103 Review.
-
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.Virchows Arch. 2024 Jan;484(1):3-14. doi: 10.1007/s00428-023-03656-w. Epub 2023 Sep 28. Virchows Arch. 2024. PMID: 37770765 Free PMC article. Review.
-
Cost analysis of archives in the pathology laboratories: from safety to management.J Clin Pathol. 2023 Oct;76(10):659-663. doi: 10.1136/jcp-2023-209035. Epub 2023 Aug 2. J Clin Pathol. 2023. PMID: 37532289 Free PMC article. Review.
-
The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective.Pathologica. 2023 Jun 14;115(3):137-47. doi: 10.32074/1591-951X-895. Online ahead of print. Pathologica. 2023. PMID: 37314870 Free PMC article. Review.
References
-
- Lindeman N.I., Cagle P.T., Aisner D.L., Arcila M.E., Beasley M.B., Bernicker E.H., Colasacco C., Dacic S., Hirsch F.R., Kerr K., et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. J. Mol. Diagn. 2018;20:129–159. doi: 10.1016/j.jmoldx.2017.11.004. - DOI - PubMed
-
- Sepulveda A.R., Hamilton S.R., Allegra C.J., Grody W., Cushman-Vokoun A.M., Funkhouser W.K., Kopetz S.E., Lieu C., Lindor N.M., Minsky B.D., et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 2017;35:1453–1486. doi: 10.1200/JCO.2016.71.9807. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
